Labcorp Holdings Inc. (LH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Labcorp Holdings Inc. (LH) Healthcare & Pipeline Overview

Labcorp Holdings Inc. (LH) is a global leader in laboratory services, offering a comprehensive suite of diagnostic and drug development solutions. With a market capitalization of $25.2B, Labcorp supports healthcare providers and pharmaceutical companies, leveraging its extensive network and data analytics capabilities within the evolving healthcare landscape.

What Is the Investment Thesis for LH?

With a market capitalization of $25.2B and a P/E ratio of 25.22, the company demonstrates financial stability. Key value drivers include the increasing demand for diagnostic testing, advancements in personalized medicine, and strategic partnerships with pharmaceutical companies. Growth catalysts include expanding its presence in emerging markets and leveraging its data analytics capabilities to improve patient outcomes. Potential risks include regulatory changes, competition from other diagnostic providers like Quest Diagnostics Incorporated (DGX), and economic downturns affecting healthcare spending. The company's dividend yield of 1.13% provides a steady income stream for investors.

Based on FMP financials and quantitative analysis

LH Key Highlights

Market capitalization of $25.2B reflects Labcorp's significant presence in the diagnostics market.

• P/E ratio of 25.22 indicates a reasonable valuation compared to its earnings.
• Profit margin of 6.7% demonstrates the company's ability to generate profits from its operations.
• Gross margin of 27.8% highlights the efficiency of Labcorp's service delivery.
• Dividend yield of 1.13% provides a steady income stream for investors.

Who Are LH's Competitors?

LH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LH's Key Strengths?

Extensive network of laboratories and patient service centers.

• Comprehensive testing menu covering a wide range of medical specialties.
• Strong relationships with healthcare providers and pharmaceutical companies.
• Data analytics capabilities providing insights for improved patient outcomes.

What Are LH's Weaknesses?

Exposure to regulatory changes and healthcare policy reforms.

• Dependence on reimbursement rates from government and private payers.
• Competition from other diagnostic providers.
• Potential for errors in diagnostic testing.

What Could Drive LH Stock Higher?

Increasing demand for diagnostic testing due to aging population and chronic diseases.

• Expansion in personalized medicine and targeted therapies.
• Potential for new strategic partnerships with pharmaceutical companies.
• Development and commercialization of innovative diagnostic tests.

What Are the Key Risks for LH?

Insider selling — insiders were net sellers of roughly $14.4M recently.

• Regulatory changes and healthcare policy reforms affecting reimbursement rates.
• Economic downturns reducing healthcare spending.
• Competition from other diagnostic providers.
• Cybersecurity threats compromising patient data.

What Are the Growth Opportunities for LH?

• Expansion in Personalized Medicine: Labcorp has a significant growth opportunity in personalized medicine, driven by advancements in genomics and proteomics. The personalized medicine market is projected to reach $2.4 trillion by 2030. By leveraging its diagnostic capabilities and data analytics, Labcorp can offer tailored treatment plans, improving patient outcomes and driving revenue growth. This includes developing and commercializing new diagnostic tests for targeted therapies, positioning Labcorp as a leader in precision healthcare.
• Strategic Partnerships with Pharmaceutical Companies: Labcorp can expand its drug development services through strategic partnerships with pharmaceutical companies. The global pharmaceutical market is expected to reach $1.7 trillion by 2027. By providing comprehensive support for clinical trials, from early-stage research to post-market surveillance, Labcorp can capture a larger share of the drug development market. These partnerships will drive revenue growth and enhance Labcorp's reputation as a trusted partner in the pharmaceutical industry.
• Geographic Expansion in Emerging Markets: Labcorp has a growth opportunity in expanding its presence in emerging markets, particularly in Asia and Latin America. These regions are experiencing rapid economic growth and increasing healthcare spending. By establishing new laboratories and patient service centers in these markets, Labcorp can tap into a large and underserved patient population. This geographic expansion will diversify Labcorp's revenue streams and reduce its reliance on mature markets.
• Leveraging Data Analytics for Improved Patient Outcomes: Labcorp can leverage its extensive data analytics capabilities to improve patient outcomes and drive revenue growth. By analyzing large datasets of patient information, Labcorp can identify patterns and trends that can inform treatment decisions and improve healthcare delivery. This includes developing predictive models to identify patients at risk for certain diseases and providing personalized recommendations for preventive care. The market for healthcare analytics is projected to reach $75 billion by 2026.
• Development of Innovative Diagnostic Tests: Labcorp can drive growth by developing and commercializing innovative diagnostic tests for a wide range of diseases. This includes developing new tests for infectious diseases, cancer, and cardiovascular disease. By staying at the forefront of diagnostic technology, Labcorp can attract new customers and increase its market share. The market for diagnostic testing is expected to continue growing, driven by the increasing prevalence of chronic diseases and the demand for early detection and diagnosis.

What Are LH's Competitive Advantages?

• Extensive network of laboratories and patient service centers.
• Comprehensive testing menu covering a wide range of medical specialties.
• Strong relationships with healthcare providers and pharmaceutical companies.
• Data analytics capabilities providing insights for improved patient outcomes.
• Brand reputation for accuracy and reliability in diagnostic testing.

What Does LH Do?

Labcorp Holdings, Inc., founded on April 16, 2024, and headquartered in Burlington, NC, is a prominent global life sciences company providing comprehensive laboratory services. The company supports doctors, hospitals, pharmaceutical companies, researchers, and patients in making informed decisions through its extensive range of diagnostic testing and drug development services. Labcorp's evolution has been marked by continuous innovation and strategic acquisitions, expanding its capabilities and geographic reach. Its core offerings include clinical laboratory testing, anatomic pathology, drug development support, and clinical trial management. Labcorp operates a vast network of laboratories and patient service centers, serving a diverse clientele across the healthcare spectrum. The company's commitment to accuracy, efficiency, and innovation has solidified its position as a trusted partner in healthcare, contributing to improved patient outcomes and advancements in medical research. With a workforce of 60,900 employees, Labcorp continues to drive advancements in diagnostics and personalized medicine, shaping the future of healthcare delivery.

What Products and Services Does LH Offer?

• Provides clinical laboratory testing services to healthcare providers.
• Offers anatomic pathology services for disease diagnosis.
• Supports drug development through clinical trial management.
• Conducts research and development to advance diagnostic technologies.
• Provides data analytics to improve patient outcomes.
• Offers comprehensive testing menus for various medical specialties.
• Operates a network of laboratories and patient service centers.

How Does LH Make Money?

• Generates revenue through diagnostic testing services.
• Earns fees for drug development support and clinical trial management.
• Partners with pharmaceutical companies for research and development.
• Provides data analytics services to healthcare providers.

What Industry Does LH Operate In?

Labcorp Holdings Inc. operates in the medical diagnostics and research industry, which is characterized by increasing demand for advanced diagnostic testing and personalized medicine. The industry is driven by technological advancements, an aging population, and the growing prevalence of chronic diseases. The competitive landscape includes major players such as Quest Diagnostics Incorporated (DGX) and smaller specialized labs. Labcorp's extensive network, comprehensive service offerings, and strategic partnerships position it favorably within this dynamic market. The industry is expected to continue growing, driven by the need for accurate and timely diagnostic information to improve patient outcomes.

Who Are LH's Key Customers?

• Doctors and other healthcare providers.
• Hospitals and clinics.
• Pharmaceutical companies.
• Researchers and academic institutions.
• Patients seeking diagnostic testing.

Over the past six months, Labcorp Holdings Inc. insiders filed 30 SEC Form 4 transactions — 18 sales and 12 purchases. On net that is roughly 41K shares acquired (about $14.4M) — insiders putting money in tends to read as conviction.

Labcorp Holdings Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 2.7% above estimates on average.

Labcorp Holdings Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.32 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Labcorp Holdings Inc. stands at 10.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.9%, showing how much profit it generates from its asset base. LH trades at a trailing price-to-earnings ratio of 25.22, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.0%, the inverse of the P/E and a quick read on earnings relative to price.

Labcorp Holdings Inc. (LH) Valuation Context

Valued at $25.2B, LH is classified as a large-cap stock. Analyst price targets span from $300.00 to $355.00, with a consensus of $328.50. At the current price of $306.96, that implies approximately 7% upside potential. Relative to its peer group, LH's quantitative score of 70/100 is roughly in line with the peer average of 73/100.

LH Revenue & Earnings Trend

In Q2 FY2026, LH generated $3.73B in top-line revenue, marking a sequential increase of 5.5%. The company recorded net income of $298.7M, with diluted EPS of $3.64. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, LH averaged $3.02 in diluted EPS.

Company Profile

Labcorp Holdings Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Burlington, US. The company is led by CEO Adam H. Schechter. LH has traded publicly since 1990.

LH Financials

LH earnings history & estimates →

LH Latest News

LH Analyst Consensus

LH MoonshotScore

Latest Labcorp Holdings Inc. Analysis

Common Questions About LH (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources